Fenwick Represents Navigating Cancer in $26 Million Series D Growth Equity Funding

Fenwick & West represented Navigating Cancer (NC), a leader in oncology patient relationship management, in raising $26 million in Series D growth equity funding. The over-subscribed round was led by the Merck Global Health Innovation Fund (GHIF) and TT Capital Partners (TTCP). Other investors in the round include BrightEdge, the American Cancer Society’s newly formed philanthropic venture fund; LabCorp®; ORIX Growth Capital; and Rustic Canyon Partners.

The funding will enable NC to accelerate innovation of its patient relationship management (PRM) platform, including delivery of a more robust mobile experience for oncology patients and the development of NC’s AI-based population care capabilities. More information about the financing can be obtained from the company’s announcement.

The Fenwick transaction team included corporate partner Alan Smith and associate Katherine Duncan.